Citius Oncology (CTOR) vs Kazia Therapeutics (KZIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Kazia Therapeutics (KZIA) has outperformed Citius Oncology (CTOR) over the past year, gaining 3.6% versus a loss of 54.8%. Kazia Therapeutics is the larger company by market cap ($82.8 million vs $81.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTOR | KZIA |
|---|---|---|
| Share price | $0.7679 | $7.25 |
| Market cap | $81.21M | $82.85M |
| 1-day change | +2.94% | -2.03% |
| YTD return | -23.21% | +5.22% |
| 1-year return | -54.83% | +3.57% |
| 5-year return | — | -98.64% |
| EPS (TTM) | $-0.48 | $-6.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-24.76M | — |
| 52-week high | $1.95 | $17.40 |
| 52-week low | $0.491 | $4.86 |
| Distance from 52-week high | -60.62% | -58.33% |
| Analyst consensus | none | none |
| Avg. price target upside | +420.90% | +290.90% |
| Average volume | 102.94K | 277.70K |
| Shares outstanding | 105.76M | 11.43M |
| Employees | — | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KZIA has outperformed CTOR by 58.4 percentage points over the past year.
About Citius Oncology
CTOR stock →Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
CTOR vs KZIA FAQ
Which is bigger, Citius Oncology or Kazia Therapeutics?
Kazia Therapeutics (KZIA) is larger, with a market capitalization of $82.85M compared with $81.21M for Citius Oncology (CTOR).
Which stock has performed better over the past year, CTOR or KZIA?
KZIA returned +3.57% over the past 12 months, compared with -54.83% for CTOR (price return, excluding dividends). Past performance does not predict future results.
Are Citius Oncology and Kazia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.